The Manufacturers Life Insurance Company Buys 142,606 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

The Manufacturers Life Insurance Company raised its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZFree Report) by 104.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 279,428 shares of the specialty pharmaceutical company’s stock after purchasing an additional 142,606 shares during the quarter. The Manufacturers Life Insurance Company owned 0.44% of Jazz Pharmaceuticals worth $34,370,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 6,379,053 shares of the specialty pharmaceutical company’s stock worth $825,705,000 after acquiring an additional 29,960 shares during the last quarter. FMR LLC increased its position in shares of Jazz Pharmaceuticals by 8.1% during the 3rd quarter. FMR LLC now owns 1,333,129 shares of the specialty pharmaceutical company’s stock valued at $172,560,000 after purchasing an additional 100,349 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Jazz Pharmaceuticals by 4.6% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,299,612 shares of the specialty pharmaceutical company’s stock valued at $168,222,000 after buying an additional 57,717 shares in the last quarter. Polaris Capital Management LLC lifted its position in Jazz Pharmaceuticals by 2.2% in the 4th quarter. Polaris Capital Management LLC now owns 1,267,460 shares of the specialty pharmaceutical company’s stock worth $155,898,000 after buying an additional 27,100 shares during the last quarter. Finally, Pacer Advisors Inc. boosted its stake in Jazz Pharmaceuticals by 28.1% in the fourth quarter. Pacer Advisors Inc. now owns 1,023,706 shares of the specialty pharmaceutical company’s stock worth $125,916,000 after buying an additional 224,865 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 5,000 shares of the firm’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $109.65, for a total transaction of $548,250.00. Following the completion of the transaction, the executive vice president now owns 36,629 shares of the company’s stock, valued at $4,016,369.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 4.40% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $195.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, February 29th. Barclays cut their price target on shares of Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Friday, May 3rd. StockNews.com upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, May 31st. UBS Group dropped their target price on Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating for the company in a report on Friday, March 1st. Finally, Stifel Nicolaus lifted their price target on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a “buy” rating in a research note on Friday, March 15th. Two research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $190.92.

Get Our Latest Stock Analysis on Jazz Pharmaceuticals

Jazz Pharmaceuticals Stock Down 0.2 %

Shares of Jazz Pharmaceuticals stock opened at $106.32 on Friday. The company’s fifty day simple moving average is $110.07 and its two-hundred day simple moving average is $117.82. Jazz Pharmaceuticals plc has a 12-month low of $103.01 and a 12-month high of $146.70. The company has a current ratio of 2.27, a quick ratio of 1.90 and a debt-to-equity ratio of 1.38. The company has a market cap of $6.70 billion, a P/E ratio of 21.92, a PEG ratio of 1.64 and a beta of 0.62.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Free Report) last released its quarterly earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.53 by ($1.55). The company had revenue of $901.98 million during the quarter, compared to the consensus estimate of $938.99 million. Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. Research analysts anticipate that Jazz Pharmaceuticals plc will post 15.35 EPS for the current year.

About Jazz Pharmaceuticals

(Free Report)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Recommended Stories

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.